PER® Chemotherapy Foundation Symposium (CFS)

Ranee Mehra, MD, discusses the link between PD-L1 expression and increased immunotherapy efficacy in head and neck squamous cell carcinoma, and what future treatment options may look like for patients in this space.

A key component of health equity includes ensuring that clinical trials reflect subgroups of patients who are more reflective of real-world populations.

As of November 2022, osimertinib is the preferred choice for the frontline treatment of EGFR-mutated non-small cell lung cancer. However, some experts believe that combination chemotherapy plus EGFR TKI will become a standard frontline treatment.

Psychiatric distress and existential distress are associated with poor outcomes in patients with advanced cancers and treatment options such as psychotherapy have demonstrated limited effectiveness.

During the 40th Annual Chemotherapy Foundation Symposium, Jeffrey S. Weber, MD, PhD, discussesed best sequencing practices in metastatic melanoma.

During the 40th Annual Chemotherapy Foundation Symposium, Eirwen M. Miller, MD, evaluated the safety and efficacy profiles of different PARP inhibitor therapies for patients with advanced ovarian cancer.

Manmeet Ahulwalia, MD, MBA, underscores how novel treatment approaches in oncology are proving effective in managing brain metastases.

During the 40th Annual Chemotherapy Foundation Symposium, Sandra Kurtin, PhD, ANP-BC, FAPO, discussed improving health literacy in oncology care.

During the 40th Annual Chemotherapy Foundation Symposium®, Hope S. Rugo, MD, FASCO, outlined key priorities for the future of breast cancer research.

Daniel J. Verina, DNP, RN, MSN, ACNP-BC, underscores how nurses can assess neurological toxicities in both the inpatient and outpatient setting.

Immunotherapy has changed the face of cancer treatment, but requires appropriate irAE management to reach full potential.

Narjust Florez, MD, emphasizes why oncology health care professionals should bring a sense of urgency to ensuring that clinical trials represent all patient populations.

There is still a great deal to learn about the optimal use of BRAF-targeted therapy, as well as immunotherapy, in the adjuvant setting for patients with melanoma.